Time trend in the survival advantage in phase III trials investigating molecular-targeted agents for advanced non-small cell lung cancer (NSCLC) during the past decade.
Yuka Kato
No relevant relationships to disclose
Katsuyuki Hotta
No relevant relationships to disclose
Hiroe Kayatani
No relevant relationships to disclose
Toshio Kubo
No relevant relationships to disclose
Kadoaki Ohashi
No relevant relationships to disclose
Masahiro Tabata
No relevant relationships to disclose
Mitsune Tanimoto
No relevant relationships to disclose
Katsuyuki Kiura
No relevant relationships to disclose